Physician profile
Todd Moore
NPI 1225014178
$847.07
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $65.54 · 2021: $171 · 2022: $67.39.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $133.95 | 2019-2021 | |
| Genentech USA, INC. | $117.50 | 2019 | |
| Lilly USA, LLC | $101.03 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.30 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $79.51 | 2019-2022 | |
| Pfizer INC. | $64.53 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.60 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $52.53 | 2019 | |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Merck Sharp & Dohme LLC | $23.80 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $23.49 | 2021 | |
| Celgene Corporation | $20.76 | 2019 | |
| Daiichi Sankyo INC. | $17.99 | 2019 | |
| Janssen Biotech, INC. | $12.79 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.44 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $11.92 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.